INTRODUCTION
A significant proportion of prostate cancer diagnoses may be associated with a strong hereditary component. 1 Recent data suggest that approximately 8% to 12% of patients with advanced prostate cancer may carry a germline mutation in a well characterized tumor-suppressor gene. 2, 3 However, genetic counseling and testing for prostate cancer have been adopted more slowly compared with other malignancies, such as breast and colon cancer. This is because of a perceived low frequency of monogenic alterations and the belief that there are complex inheritance patterns involving multiple singlenucleotide polymorphisms (SNPs) in what is a genetically heterogeneous disease. 4 These concerns are becoming increasingly tempered by ongoing advancements in sequencing technologies, and the emergence of next-generation sequencing has allowed for an easier method for both somatic and germline genomic evaluation. 5 Because it is now recognized that the results of these tests influence therapeutic strategies, there has been renewed interest in genomic testing for patients with prostate cancer, especially for those who have evidence of a familial predisposition. Herein, we review complex issues and barriers in the evaluation and testing of patients with prostate cancer.
EVIDENCE FOR HEREDITARY PROSTATE CANCER PREDISPOSITION
Over the past few decades, various malignancies, including breast, ovarian, colorectal, and kidney cancers, have been associated with hereditary syndromes. Although it has long been recognized that some patients may have a hereditary predisposition to prostate cancer, establishing a causal genetic relation has remained challenging because of the high incidence of prostate cancer, the low frequency of the known cancer syndromes, and complex inheritance patterns. In addition, a standard definition of which individuals are at risk for hereditary prostate cancer has not been adopted. Thus, as the field of prostate cancer genetic continues to grow, the added capability of genetic counseling and testing will help further refine our understanding of who is at greatest risk.
Family history is an established risk factor for the development of prostate cancer. Indeed, 1 study estimates that 8% of all prostate cancers are caused by high-risk heritable factors. 6 In patients affected with prostate cancer, the heritability (the proportion of prostate cancer variation attributed to germline genetics) is approximately 58%. 7 Familial studies, including those that have assessed concordance among monozygotic and dizygotic twins, have demonstrated an increased risk of prostate cancer if a sibling is affected. 1 Compared with the general population, men who have a first-degree relative with prostate cancer have a 2-fold increased risk of developing the disease. 8 The risk varies modestly, depending on which family member is affected, such that an individual with a brother or father diagnosed with prostate cancer at any age harbors a relative risk (RR) of developing prostate cancer of 3.1 and 2.4, respectively. 9 Because there are environmental causes that family members may share, it is important to understand that the increased risk is related to a heritable component. Among patients in the Massachusetts Male Aging Study cohort, those who had a family history of prostate cancer had a 3.8-fold RR of prostate cancer diagnosis compared with those who had no family history, even when adjusting for environmental factors. 10 This risk also increases with an increasing number of affected relatives and if individuals have an earlier age of onset. 9 Collectively, these studies indicate the significant role of family history in prostate cancer predisposition.
Often, families can report a group of malignancies that may have a linked heritable component, like hemangioblastoma, clear cell renal carcinoma, and pheochromocytoma in von Hippel-Lindau (VHL) disease. It has been recognized that prostate cancer is commonly identified in families with a high predisposition to cancer of the breast and ovary. In an Iowa cohort study, men with either a mother or a mother or sister who had breast/ovarian cancer (without information on germline status) had an elevated RR of prostate cancer (mother: RR, 2.0; 95% confidence interval [CI], 1.0-4.1; mother or sister: RR, 1.7; 95% CI, 1.0-3.0). This risk is even greater in families with both prostate and breast/ovarian cancer (RR, 5.8; 95% CI, 2.4-14). 11 Although some of this risk may be associated with carrying a known germline mutation in hereditary breast/ovarian cancer genes (discussed below), the RR may exceed the expected contribution because of the more common cancer syndromes.
Racial groups share common genomic polymorphisms that can contribute to cancer predisposition. African Americans have a nearly 2 and 3 times higher incidence of prostate cancer compared with Caucasians and Asians, respectively. 12 However, some of this may be attributable to environmental risk factors, such as diet and obesity, as well as screening patterns within an ethnic/ racial community. These modifiable risk factors can significantly influence population risk. This is best exemplified by a significant increase in prostate cancer incidence with migration and adoption of a new culture, as demonstrated in multiple ethnic groups. [13] [14] [15] GENETIC BASIS OF PROSTATE CANCER PREDISPOSITION A host of studies evaluating the genetics underlying prostate cancer predisposition has examined SNPs and single gene alterations. Common among many of these studies are evaluation of patient cohorts with extensive family history or early onset prostate cancer. Below is a summary of our current understanding of some of the heritable factors associated with prostate cancer.
SNPs Associated With Prostate Cancer
To date, numerous genome-wide association studies have identified over 100 SNPs associated with prostate cancer in populations of European and non-European descent. Although many of these SNPs have been externally validated and confirmed to increase risk, no single locus has been universally identified to justify consistent testing or to guide screening recommendations. In 1 systematic review that catalogued over 20 different genome-wide association studies and more than 70 SNPs, the risk of prostate cancer associated with any individual SNP was fairly small, with an odds ratio (OR) ranging from 0.74 to 1.79. 16 It is noteworthy that there is 1 specific chromosomal locus at 8q24 (the long arm of chromosome 8 at position 24; near the MYC proto-oncogene) where several SNPs have been associated with prostate cancer susceptibility among various ethnicities. 17, 18 Because 1 individual region may confer a slightly elevated risk, it has been proposed that testing of a large number of regions could be of clinical utility. A previous study evaluated whether a population of men who carried multiple SNPs associated with a predisposition to prostate cancer and a family history of prostate cancer would be useful in predicting the future risk of developing prostate cancer. In that study, men who had more than 4 risk alleles had a 4.5 times greater risk of developing prostate cancer. Notably, those who had 4 or more risk alleles in addition to a family history of prostate cancer had a nearly 10-fold increased risk for prostate cancer. 19 Those results were further corroborated in another study using populations from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial in the United States and the Cancer of the Prostate Study in Sweden, which reported an elevated risk in men who had multiple risk alleles and a family history. 20 Together, these studies indicate that, although knowledge regarding 1 risk allele may have limited utility, a combination of multiple alleles in addition to a family history of prostate cancer may provide meaningful prognostic ability. Although these risk alleles may provide insight into cancer development, the underlying mechanisms remain unclear, because most prostate cancer risk alleles are located in the noncoding regions of the genome and would not alter protein function. However, it is increasingly recognized that noncoding alterations can influence gene expression and splicing, which can contribute to cancer risk. 21 On the basis of the currently available literature, the Agency of Healthcare Research and Quality has concluded that an assessment of SNPs does not provide an incremental gain to risk assessment.
Genes Associated With Prostate Cancer
Several studies [22] [23] [24] [25] [26] [27] [28] have demonstrated increased risk of prostate cancer with mutations in known prostate cancer susceptibility genes (Table 1) . 2, [22] [23] [24] [25] 27, [29] [30] [31] [32] [33] [34] [35] [36] Although conventional opinion has held that the prevalence of patients with prostate cancer harboring germline alterations was quite low, recent data challenge that notion. A landmark study examined the mutational status of 20 DNA-repair genes among a cohort of 692 patients with metastatic prostate cancer. The authors identified a fairly high incidence of germline alterations in many of the genes tested, including breast cancer gene 2 (BRCA2), ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHEK2), BRCA1, RAD51 paralog D (RAD51D), and partner and localizer of BRCA2 (PALB2). The overall mutation frequency in the men who had metastatic prostate cancer was 11.8% compared with 4.6% in those with localized disease, and 2.7% in those without cancer. 3 Because disease stage is significantly associated with the likelihood of carrying a germline alteration, this suggests that those with DNA-repair defects will likely experience a worse disease course.
Germline alterations in either of the BRCA genes (BRCA1 and BRCA2) are associated with breast and ovarian cancer. Germline alterations in these genes have now been associated with other cancers, such as melanoma, pancreatic cancer, and prostate cancer. Specifically, it is believed that alterations in BRCA1, located on chromosome 17q21, result in an increased RR (ranging from 1.8 to 3.75) of prostate cancer by age 65 years. 27, 29 It has been demonstrated that alterations in BRCA2, located on chromosome 13q12.3, significantly elevate RR, ranging from 2.5 to 4.6. 30, 37 Patients who have BRCA2 mutations also appear to be more susceptible to early onset prostate cancer (age 55 years), with an RR increase ranging from 8 to 23. 24, 31 Individuals who have prostate with BRCA1/ BRCA2 alterations more frequently have higher grade (Gleason 8) and higher stage disease as well as a greater incidence of lymph node involvement and metastases compared with those who have sporadic prostate cancer. 38 Patients with BRCA2 alterations may be at the greatest risk; and, despite controlling for other variables, the presence of a germline alteration in this gene is an independent predictor of metastases and worse cancer-specific survival.
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The DNA MMR genes, MLH1, MSH2, MSH6, and PMS2, are located in band 21.3 of the short arm of 32 Although it has been demonstrated that these mutations are be associated with an increased risk of prostate cancer, their role in tumorigenesis has not been fully elucidated. Mechanistic studies may be required to confirm that germline alterations in these genes play a role in prostate cancer development. Nevertheless, several studies have revealed that prostate tumors in patients with known MMR mutations were MMR-deficient, suggesting that an additional somatic event contributed to cancer development. Collectively, these studies support a role for these germline mutations in conferring prostate cancer predisposition.
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CHEK2, located on band 12.1 of the long arm of chromosome 22 (22q12.1), codes for a cell-cycle checkpoint protein kinase that plays a role in the regulation of tumor protein 53 (TP53) and DNA repair. Alterations in CHEK2 have been linked to wild-type TP53 Li-Fraumeni syndrome, and germline alterations in CHEK2 have been linked to an increased risk of breast cancer. 42 Recently, it has been observed that alterations in CHEK2 also increase the risk of other cancers, such as colon, thyroid, kidney, and prostate cancers. 43 A study by Dong et al identified 28 CHEK2 germline mutations in 578 patients with prostate cancer (28 of 578 patients; 4.8%) in contrast to 6 mutations in 423 unaffected patients (6 of 423 patients; 1.4%), suggesting that a mutation in this gene may confer an increased risk of prostate cancer. 23 In addition, a systematic review and meta-analysis of 8 studies of common CHEK2 mutations indicated that individuals who had a cytidine deletion at position 1100 (1100delC) (OR, 3.29; 95% CI, 1.85-5.85; P 5 .00) or an isoleucine-tothreonine mutation at nucleotide 157 (I157T) increased the RR of prostate cancer by 3.3 and 1.8, respectively. 34 ATM plays a key role in the DNA damage response mechanism. Homozygous loss-of-function mutations in ATM cause ataxia telangiectasia syndrome, which is characteristically manifested by severe neurodegeneration. In addition, it has been reported that carriers of ATM mutations are at increased risk for breast, colorectal, gastric, and pancreatic cancers. In recent, large-scale, targeted sequencing efforts, which included panels of DNA-repair genes, germline alterations in ATM were further evaluated as potential markers for hereditary prostate cancer. Before those studies, there had been limited work investigating a potential role for ATM in prostate cancer predisposition. Various studies now confirm that germline alterations in ATM can be identified in men who have prostate cancer. 36 Further evidence that germline alterations in ATM contribute to the risk of prostate cancer was produced by comparing their frequency in patients who had prostate cancer with a population of noncancer controls in the Exome Aggregation Consortium (EXAC). The estimated RR of metastatic prostate cancer in ATM carriers was 6.3 (95% CI, 3.2-11.3; P < .001).
3 Furthermore, data indicate that these carriers have a worse prognosis compared with men who have sporadic prostate cancer. 44 The identification of mutations in DNA-repair genes like BRCA1/ BRCA2 and ATM in men with metastatic castrateresistant prostate cancer (mCRPC) is of clinical importance, because emerging data indicate that the use of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors can lead to an increased response rate in these settings.
Another gene of interest includes BRCA1-interacting protein C-terminal helicase 1 (BRIP1), a member of the RecQ DEAH helicase family, which plays a role in double-strand DNA break repair function with BRCA1. BRIP1 loss of function has been associated with familial prostate cancer.
2 One case-control study identified a BRIP1 truncating mutation in familial and youngonset prostate cancer. 35 The same truncating mutation was not observed in a similar, smaller study in the United States, hence further validation is needed. 45 A recent report did identify a single patient with a BRIP1 germline alteration (1 of 692 patients; 0.18%); however, this is similar to what is reported in the EXAC registry. 3 Genetic linkage studies have implicated variants at chromosome 17q21 with increased risk of prostate cancer. Ewing and colleagues reported that recurrent germline mutations in homeobox B13 (HOXB13), located at 17q21.32, were associated with prostate cancer susceptibility. Among its various functions in embryonic development and regulation of androgen receptor target genes, HOXB13 reportedly functions as a tumor suppressor in cancer; however, the mechanism by which HOXB13 mutation leads to prostate cancer is unknown. 46 It has been demonstrated that HOXB13 mutations are more common in early onset disease. 47 One study reported very high penetrance, with 60% of individuals developing prostate cancer by the age 80 years. 47 A specific germline alteration in this gene (glycine-to-glutamic acid substitution at position 84 [G84E]) increases the risk of prostate Review Article cancer with an OR ranging from 3.2 to 7.9. 25, 33, 48 The frequency of G84E carriers varies by population, with estimates ranging between 0.66% and 6.25%. 49 Nibrin (NBN) or Nijmegen breakage syndrome 1 (NBS1), located on chromosome 8q21, codes for the protein Nibrin, which is a member of the Mre11-RAD50-NBS1 (MRN) double-strand DNA break repair complex. Studies have demonstrated that deletion of MRN is incompatible with life. 50 Recently, NBN has emerged as a prostate cancer-susceptibility gene. Specifically, the variant c.657del5 is more prevalent in patients who have familial rather than nonfamilial forms of prostate cancer. 22 The risk of developing prostate cancer is approximately 2.5-fold higher for unselected patients and 4.3-fold for those with a known family history. Furthermore, there is evidence that mutations in NBN may predispose patients to higher grade disease. 51 Although these guidelines share similarities, there is still a clear need to establish uniform guidelines for risk assessment. It was recently reported that expanding testing to patients with a second cancer diagnosis may identify germline cancer alterations in >10% of individuals; however, restricting testing to the above guidelines may miss the majority of these patients. 36 Apart from using the strict guidelines described above, we suggest specific attention to the individual's age at diagnosis when assessing hereditary risk. Although prostate cancer has been considered a disease of the elderly (with median age of 66 years at onset), patients who have a history of familial prostate cancer or a genetic predisposition are more likely to have an earlier age of onset. 55, 56 The bottom decile of prostate cancer cases are diagnosed in men aged 55 years, an age that has been considered early onset and useful for referral to counseling (Fig. 1) . 57 The association of age with genetic alterations has led to suggestions that relatives of affected individuals should begin standard prostate cancer screening earlier than the general population but that this still should be an informed decision based on physician and patient preference.
THE ROLE OF GENETIC COUNSELING, RISK ASSESSMENT, AND TESTING GUIDELINES
Ideally, a genetic counseling appointment consists of an evaluation by a licensed genetic counselor and examination by a physician. Pretest and posttest genetic counseling are essential components, and we believe that germline analysis should not be performed in the absence of referral to an experienced provider/team. The American Society of Clinical Oncology supports this concept and recommends that patients receive extensive pretest counseling and informed consent before any testing. 58 There have been recent efforts to encourage clinicians who are not experienced with genetics to order germline testing; however, our team has demonstrated that significant errors in interpretation can occur in this setting, leading to unnecessary interventions, liability, and increased health care costs. 59 At a counseling visit, a genetic counselor takes a detailed personal and family history of cancer and associated conditions, examines the family pedigree, informs the patient of their potential hereditary cancer risk, explains the implications of a particular cancer, and discusses the benefits and limitations of genetic testing. In these evaluations, a family pedigree is useful in analyzing the inheritance pattern of cancers and allows genetic counselors to evaluate the candidacy of either the patient or the family member for genetic testing. Furthermore, a pedigree aids in the assessment of familial risk for cancer and provides insight into possible disease segregation (Fig.  2) . After an interview with the genetic counselor, it may be helpful for a clinical geneticist or a physician with a focus on hereditary syndromes to perform a complete history and physical examination possibly to elucidate subtle disease manifestations. If indicated, and once the patient has agreed to genetic testing, the genetic counseling team will then coordinate with laboratories to provide the appropriate genetic testing. A posttest genetic counseling meeting is essential, because it allows for a detailed review of findings, which may include a known deleterious/pathogenic (positive) variant, a variant of uncertain significant, or a negative result. Although some patients may request posttest counseling remotely, we strongly advise a detailed second visit because of the complexity of the discussion, and because testing contains implications limited not only to the patient but also to the status of family members at large. These posttest visits provide further support to approach other family members at risk, educational resources, and clinician referrals and enable patients to make informed decisions regarding their own care.
Issues Related to Insurance Coverage
Genetic counseling and testing may be associated with significant costs to the patient. In addition to meeting with a counselor, costs include acquisition of a specimen (either a blood collection or buccal/saliva specimen) and the specific test ordered. Depending on whether a single gene or a multigene panel test is performed, costs can vary widely. Multigene panel costs also vary significantly by panel size and by laboratory. Many testing laboratories are willing to submit a preauthorization to the insurance company after receiving the sample before proceeding with the test. In this situation, once the laboratory confirms the extent of coverage and the anticipated costs, the patient is contacted to determine whether to proceed with testing.
Coverage for genetic testing continues to evolve as we continue to identify more genes associated with cancer predisposition. Unlike breast cancer, in which there has been nearly 2 decades of refinement in testing practices, the field of prostate cancer germline testing in the clinical setting is in its infancy. Currently, most major insurers do not universally cover prostate cancer genetic testing. Coverage may exist for certain prostate cancer-associated genes if specific criteria are met for other hereditary conditions. The coverage policy for genetic testing is also nonspecific and nonuniform, with each company requiring specific criteria to be met before approval of testing coverage (Table 2 ). This hinders the process of evaluating individuals with a strong personal and familial history and may deter the pursuit of genetic counseling/testing in patients who cannot afford the out-of-pocket costs. Nevertheless, most companies offer financial assistance programs and reduced out-of-pocket costs for patients who lack insurance coverage. Further research is needed to inform who should be tested and define the relevance of results to the patient and their family.
Genetic Testing for Germline Alterations
The primary goal of genetic counseling is to identify patients who may benefit from genetic testing. On the basis of the suspicion of a hereditary syndrome from either clinical characteristics or a family pedigree, single-gene tests may be ordered to identify a specific germline alteration. The identification of a particular alteration serves as confirmation of a hereditary syndrome, which can shape long-term management strategies, surveillance for prostate cancer (in unaffected individuals), and other manifestations. The use of a single-gene test is most feasible for a monogenic syndrome, with previously established causal correlations and strong disease segregation. However, for conditions such as Lynch syndrome, multiple genes may contribute to the presentation of disease, and testing for a single gene may be inefficient. Furthermore, other (particularly newly characterized) syndromes may present with more subtle and less penetrant disease manifestations, which can be difficult to diagnose; therefore, it is useful to include them in a wider panel.
Significant advances in technology have led to a dramatic reduction in the costs of sequencing, allowing for the introduction of multiple genes on a single panel test. 60 Traditional single-gene testing generally has been low-yield and time-intensive, because time is invested in waiting for results from each subsequent test before proceeding to a diagnosis or clinical intervention. Furthermore, a negative test result may indicate to the clinician that the appropriate germline alteration has yet to be identified. Therefore, multigene panel testing reduces the waiting time until a definitive diagnosis is reached. Moreover, compared with singlegene testing, multigene panel testing may lead to the identification of additional germline alterations because of the incorporation of a larger genetic screening pool. 61 Because prostate cancer is so common, it has been considered a lucrative opportunity for commercial genetic testing companies to move into this space. In recent years, large companies have begun to offer multigene prostatespecific panels. These include Myriad Genetics (Salt Lake City, UT), Ambry Genetics (Aliso Viejo, CA), Color Genomics (Burlingame, CA), and Invitae Corporation (San Francisco, CA). Each laboratory offers similar testing on prostate-associated genes, including ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, and TP53 (Table 3) .
SOMATIC TUMOR PROFILING AND GERMLINE IMPLICATIONS:
Tumor profiling with next-generation sequencing is rapidly gaining traction in oncology to determine driver alterations and assist with the selection of biomarkerbased anticancer therapy. In prostate cancer, the past 2 years have witnessed a rapid uptake in tumor profiling, because several landmark studies have demonstrated that specific alterations may be predictive biomarkers of response to therapy. In men with mCRPC who have DNA-repair defects identified on targeted sequencing, there is increased response and progression-free survival with PARP inhibition (olaparib). 62 The Food and Drug Administration (FDA) recently approved olaparib for the treatment of BRCA1/BRCA2-mutated or ATM-mutated mCRPC in patients who received prior taxane-based chemotherapy and prior abiraterone or enzalutamide. Various novel clinical trials are exploring the use of olaparib and other PARP inhibitors in earlier stages of disease. Because of the therapeutic implications, some experts have advocated for routine testing of all men with mCRPC for the presence of germline or somatic mutations of DNA-repair genes. 3 Several genomic testing companies including Foundation Medicine Inc (Cambridge, MA), 1 Caris Life Sciences (Irving, TX), and bioTheranostics (San Diego, CA) offer services using either tissue biopsy, a surgical specimen, or a blood sample (Table 4) . These platforms may test for mutations in as many as 300 or more cancerrelated genes and for molecular rearrangements, such as translocations and copy number alterations. Currently, most companies do not use a germline sample as a control; therefore, the presence of an alteration prompts the question of whether it is inherited or somatic. The implications of such findings cannot be understated, because they affect not only the patient who may be at risk for the development of other cancers but also the individual's relatives who also may be at risk for developing a similar cancer. Any patient who has an alteration in a gene that has a known association with a hereditary cancer syndrome should be referred to a genetic counseling program to determine whether further testing is indicated. Although the allele frequency may be indicative of a germline versus somatic alteration, it is essential to confirm any suspicion with germline testing of the gene in question. To save costs, many tests sequence specific hotspots that are frequently altered rather than the whole gene. Therefore, the absence of a somatic alteration in a hereditary gene does not exclude the possibility that it is present in a different region. Although this strategy may provide high sensitivity and specificity for the identification of somatic alterations, the pattern of germline inactivation of a tumorsuppressor gene may differ, depending on the gene. Therefore, it is important to note whether an entire tumor-suppressor gene is being evaluated. Even when a hereditary cancer syndrome is associated with tumor development, during cancer progression, a heterozygous deletion of the mutant allele can occur in theory, making detection of a germline variant challenging. Because a tumor is a mixed population of cancer cells and normal cells, next-generation sequencing with high coverage should be able to detect this situation with a low allele frequency. However, with classic Sanger sequencing, this situation may have the potential to miss a germline variant in a highly pure tumor. Several issues may occur in the assessment of sequencing results from tumor profiling. The frequency of alterations appears to differ among genes involved in the DNA-repair pathway at different stages of the disease. 3 Because specific subclonal lineages may be selected for during and after therapy, if these defects develop as late events, then testing tissue from the primary tumor may not provide sufficient insight into the current disease biology. Specific strategies have evolved to overcome intertumoral and intratumoral heterogeneity and temporal changes with disease progression with the introduction of a liquid biopsy to evaluate circulating cell-free DNA from a blood draw. Various platforms (Table 4) . Because of the nature of circulating tumor DNA (ctDNA) in blood, both somatic and germline alterations may be detected. Most of these methods rely on purifying plasma cell-free DNA with the hope of detecting ctDNA within this population. Contamination with normal DNA from lymphocytes or from nonneoplastic cell-free DNA can make the detection of ctDNA challenging. The allele frequency of a detectable variant from ctDNA is generally less than 5%. 63 Because individuals with a germline alteration would be expected to have 50% of the sequencing reads harboring a mutation, it should be possible to determine whether a variant is somatic or germline. Because occasional outliers with a high mutant allele frequency may be present, germline testing in these cases would be useful for confirmation of results.
Various pitfalls of inappropriate interpretation of tumor profiling have been caught by our Yale Cancer Genetics and Prevention Program. To assist with the interpretation of tumor-profiling results, as they may pertain to the incidental detection of a germline condition, the American College of Medical Genetics has put forth guidelines to aid laboratories in how to best report findings in hereditary cancer genes. 64 We recommend that, as mentioned above, any individual who has an alteration identified in a cancer gene that also has been associated with a hereditary cancer syndrome should be referred to a cancer genetics program for evaluation.
With both somatic and germline alterations known to occur in genes associated with hereditary cancer syndromes, currently, there is no optimal method for evaluating individuals with prostate cancer. There are benefits and pitfalls with any approach taken (Table 5) . Therefore, as a field, we must identify the most cost-effective approach while maintaining sensitivity and specificity. Because current tests are not comprehensive, it may be necessary to use multiple modalities for testing, in that both germline and somatic results are relevant to patient care (Fig. 3) . With ctDNA providing insight into the cancer present at the time of testing (as opposed to an archival sample) while allowing for inference into the germline (based on the allele frequency), we believe that adaptation/expansion of these ctDNA platforms potentially may become a preferred testing option as long as there is germline validation.
CONCLUSION
It has long been recognized that prostate cancer has a significant genetic component. A strong family history and early age of diagnosis are strong indicators of a contributing germline alteration. Many known cancersusceptibility genes have been identified as contributing to the risk of prostate cancer development. Although numerous SNPs have been associated with prostate cancer, single loci appear to provide a low contribution to risk, and the use of multi-SNP panels is not currently recommended. Advancement in multigene panel testing has enabled the simultaneous and efficient testing of multiple germline variants. There are inherent complex issues and implications regarding somatic and germline testing for prostate cancer. The emergence of pharmacotherapy targeted at specific driver genes, including DNA MMR genes, has established that the identification of somatic and germline alterations through testing can influence treatment. When feasible, testing should be done in the presence of an experienced team of physicians and genetic counselors to provide appropriate pretest and posttest guidance to patients, allowing them to make informed decisions. Currently, a clear policy regarding genetic testing is not uniform among experts or insurers, further hindering access to testing and the development of personalized care. 
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